<DOC>
	<DOCNO>NCT02213328</DOCNO>
	<brief_summary>Truvada ( emtricitabine/tenofovir disoproxil fumarate , FTC/TDF ) type antiretroviral ( ARV ) medicine commonly use treat HIV . Truvada also use pre-exposure prophylaxis ( PrEP ) prevent HIV infection HIV-negative adult . The purpose study evaluate acceptability , safety , use daily Truvada PrEP part comprehensive HIV prevention package healthy , HIV-uninfected adolescent 15 19 year age .</brief_summary>
	<brief_title>Evaluating Acceptability , Safety , Use Daily Truvada Pre-Exposure Prophylaxis Healthy , HIV-Uninfected Adolescents</brief_title>
	<detailed_description>Truvada PrEP approach use protect HIV-uninfected adult possible infection HIV . The approach involve take Truvada every day prevent HIV infection case person expose HIV ( example , sex HIV-infected person ) . The purpose study evaluate acceptability , safety , use daily Truvada PrEP part comprehensive HIV prevention package healthy , HIV-uninfected adolescent 15 19 year old . In addition Truvada PrEP , HIV prevention package include HIV test , management sexually transmit infection ( STIs ) , risk reduction counseling , access condom , post-exposure prophylaxis ( PEP ) , circumcision counsel referral male participant . The study enroll 150 healthy , HIV-uninfected adolescent 15 19 year age . The study last 12 month ( 52 week ) involve schedule clinic visit study entry ( Week 0 ) Weeks 4 , 8 , 12 , 24 , 36 , 48 , 52 . For first 12 week study , participant provide supply Truvada tablet take daily part comprehensive HIV prevention package . At Weeks 12 , 24 , 36 , 48 , participant offer follow option : continue full HIV prevention package plus Truvada PrEP , stop Truvada PrEP continue rest HIV prevention package , re-start Truvada PrEP previously stop . After Week 12 study , Truvada tablets give participant decide take PrEP medical reason . Regardless whether choose use Truvada PrEP Week 12 , study participant follow Week 52 study . All study visit include blood collection , counsel HIV testing , urine collection pregnancy test ( female participant ) , completion sexual risk behavior questionnaire , receipt supply condom , contraceptive counseling , medical history review , disclosure available test result . Select study visit may include physical exam , blood urine collection , test treatment STIs , adherence counseling , acceptability assessment . Between Months 11 12 study , participant randomly select participate focus group discuss experience take Truvada PrEP .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Age 15 19 year ( inclusive ) screening , verify per study site standard operating procedure ( SOPs ) Able willing provide write inform consent/assent ( age dependent ) screen take part study Have guardian able willing provide write informed consent child screen take part study Able willing provide adequate locator information , define site standard operating procedure ( SOPs ) HIVuninfected base test perform study staff screen enrollment Sexually active , define minimum one act ( penile vaginal ) sexual intercourse last 12 month , per selfreport ( For female participant ) Negative pregnancy test screening enrollment , per participant report , intend become pregnant next 12 month ( For female participant ) Using effective method contraception enrollment , intend use effective method study duration ; effective method include low dose oral , implant , injectable hormonal method . Does report intention relocate study area course study Does job obligation would require long absence area ( 4 week time ) Willing undergo studyrequired procedure At screen enrollment , agree participate research study involve drug medical device next 12 month Participants meet follow criterion , baseline , exclude study : As determine Site Investigator , significant uncontrolled active chronic disease process limit diabetes , hypertension , diseases involve cardiovascular , pulmonary , gastrointestinal , genitourinary , musculoskeletal , central nervous system Confirmed Grade 2 great hypophosphatemia Presence serious psychiatric symptom ( e.g. , active hallucination ) Visibly distraught time consent ( e.g. , suicidal , homicidal , exhibit violent behavior ) Intoxicated influence alcohol drug time consent Acute chronic hepatitis B infection ( i.e. , hepatitis B surface antigen positive ) Hepatitis B seronegative refuse vaccination Renal dysfunction ( creatinine clearance le 75 ml/min ) ; Use CockroftGault equation detail protocol Urine dipstick protein glucose , exclude value `` 1 + '' great Any history bone fracture explain trauma Any Grade 2 great toxicity screen test assessment Concurrent participation HIV vaccine study investigational drug study Known allergy/sensitivity study drug component Use disallow medication ( detailed protocol )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>